INCREASE OF DRUG BIDOSTASTICITY AT THERAPY BY NALTREXONE Russian patent published in 2018 - IPC A61M21/00 A61K31/135 A61K31/485 A61P3/04 

FIELD: pharmacology.

SUBSTANCE: methods and a pharmaceutical combination are proposed. They are based on pharmaceutical composition application with food. A pharmaceutical composition comprising a daily dosage of about 8 mg to about 32 mg of sustained-release naltrexone or a pharmaceutically acceptable salt thereof and a daily dosage of about 90 mg to about 360 mg of sustained-release bupropion or a pharmaceutically acceptable salt thereof is used. Food that should provide the following pharmacokinetic parameters is selected: less than 3.7-fold increase in C_max and 2.1-fold increase in PPC of naltrexone introduced after administration of a single dose of the said pharmaceutical composition as compared to C_max and PPC when the said composition is administered without food. Food should also provide a less than 1.8-fold increase in C_max and a 1.4-fold increase in PPC of the administered bupropion after administration of a single dose of the said pharmaceutical composition as compared to C_max and PPC when the said composition is administered without food.

EFFECT: inventions provide effective treatment by increasing the stability of pharmacokinetics and increasing the bioavailability of the drugs administered, more effective dosing, reducing frequency and severity of their side effects when using a certain food composition.

23 cl, 4 tbl, 1 dwg, 4 ex